Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The concept of 'equipoise', or the 'uncertainty principle', has been represented as a central ethical principle, and holds that a subject may be enrolled in a randomized controlled trial (RCT) only if there is true uncertainty about which of the trial arms is most likely to benefit the patient. We sought to estimate the frequency with which equipoise conditions were met in industry-sponsored RCTs in rheumatology, to explore the reasons for any deviations from equipoise, to examine the concept of 'design bias', and to consider alternative ethical formulations that might improve subject safety and autonomy. We studied abstracts accepted for the 2001 American College of Rheumatology meetings that reported RCTs, acknowledged industry sponsorship, and had clinical end-points (n = 45), and examined the proportion of studies that favored the registration or marketing of the sponsor's drug. In every trial (45/45) results were favorable to the sponsor, indicating that results could have been predicted in advance solely by knowledge of sponsorship (P < 0.0001). Equipoise clearly was being systematically violated. Publication bias appeared to be an incomplete explanation for this dramatic result; this bias occurs after a study is completed. Rather, we hypothesize that 'design bias', in which extensive preliminary data are used to design studies with a high likelihood of being positive, is the major cause of the asymmetric results. Design 'bias' occurs before the trial is begun and is inconsistent with the equipoise principle. However, design bias increases scientific efficiency, decreases drug development costs, and limits the number of subjects required, probably reducing aggregate risks to participants. Conceptual and ethical issues were found with the equipoise principle, which encourages performance of negative studies; ignores patient values, patient autonomy, and social benefits; is applied at a conceptually inappropriate decision point (after randomization rather than before); and is in conflict with the Belmont, Nuremberg, and other sets of ethical principles, as well as with US Food and Drug Administration procedures. We propose a principle of 'positive expected outcomes', which informs the assessment that a trial is ethical, together with a restatement of the priority of personal autonomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339 · cited 1×
“[ 2 ,3]. ‘Zones of indifference’ could be constructed around the equipoise (50:50) point.”
BackgroundScope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816 · cited 2×
“Certainly, skepticism and vigilance are required with industrysponsored trials because there are inevitably large financial interests, and omitted results, redundant presentations, and marketing ‘spin’ do sometimes occur [18,19,29,31].”
BackgroundAls-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Publication Bias in Editorial Decision Making
Olson, C. M. (2002) · JAMA · doi:10.1001/jama.287.21.2825 · Cited by 395 · cited 1×
“However, the magnitude of publication bias remains controversial, and a number of studies suggest that this type of bias has only small effects [21–24], whereas our observed effects are huge.”
BackgroundMills, N., Donovan, J. L., Smith, M., Jacoby, A., Neal, D. E., & Hamdy, F. C. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00020-5 · Cited by 142 · cited 1×
“It was recently argued that perceptions of basic fairness (not necessarily equipoise) are important to the decision to accept a trial [5].”
Background
Cited by
Martell, B. A., O'Connor, P. G., Kerns, R. D., Becker, W. C., Morales, K. H., Kosten, T. R., & Fiellin, D. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00006 · Cited by 774
Pharmaceutical company funding and its consequences: A qualitative systematic review
Sismondo, S. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2007.08.001 · Cited by 304
Ridker, P. M., & Torres, J. (2006) · JAMA · doi:10.1001/jama.295.19.2270 · Cited by 303
Randomized controlled trials – a matter of design
Siepmann, T., Spieth, P. M., Kubasch, A. S., Penzlin, A. I., Illigens, B. M.-W., & Barlinn, K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s101938 · Cited by 292
“serious biases may be introduced (eg, selection bias – less severely affected stroke patients with basilar artery occlusion are more likely cleared for randomization than more severely affected patients).(38) Preplanned interims analyses at certain time points or recruited sample sizes during an ongoing RCT aid in mai…”
BackgroundParkhurst, J. (2016) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · doi:10.4324/9781315675008 · Cited by 756
Metadata
- Authors
- Fries, J. F., & Krishnan, E.
- Venue
- Arthritis Res Ther
- Published
- 2004-03-18
- Volume
- 6
- Issue
- 3
- Pages
- R250-5
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1523498755
- Cited by
- 142
- References
- 5
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.